Voronoi Signs Technology Transfer Option Agreement with US Biotech Anvia

Voronoi announced on the 26th that it has signed a contract with Anvia Therapeutics, Inc. (hereinafter Anvia) in the United States.

The contract grants Anvia an exclusive option to acquire Voronoi's pipeline VRN04. Anvia is a company established by Deerfield. It is a U.S. biotech developing a pipeline of small molecule therapeutics for chronic inflammatory and autoimmune diseases.

Voronoi will receive 2.5 million shares of Anvia's common stock as a signing fee. Anvia will additionally provide funds necessary for the final candidate selection of VRN04. If Anvia exercises the option to acquire VRN04, Voronoi will receive additional equity and cash according to the transfer agreement.

Daegwon Kim, Head of Research at Voronoi, explained, "We have high expectations for Anvia in developing an oral RIPK1 therapeutic for autoimmune diseases."

Hyuntae Kim, Head of Management, said, "We are pleased to announce the contract with Anvia," and emphasized, "We will continue to collaborate with U.S. biotech companies established by leading U.S. healthcare specialized investors like Deerfield to develop new drugs in areas where no treatments currently exist, as in this case."